Skip to main content
Equibles

TLX · Telix Pharmaceuticals Ltd · Metrics

Track TLX — free

Use TLX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TLX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.03 -1.13 (-10.13%) At close · Oct 21
Rebalance outlook locked
Market Cap
$3.41B
Shares
338.78M
Volume · Oct 21 879.08K Avg daily vol (3M) 291.28K

TLX metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.03
Market cap
$3.41B

Price action

20 metrics
Price change (1W)
-5.8%
Price change (30D)
-16.1%
Price change (3M)
-2.8%
Price change (6M)
-2.9%
Price change (YTD)
+33.9%
Price change (1Y)
-8.2%
Trailing year
Price change (5Y)
—
52-week high
$12.83
52-week low
$6.41
Change from 52-week high
-21.8%
Change from 52-week low
+56.5%
Annualized volatility
55.7%
Annualized volatility (3M)
61.0%
Beta
1.0
RSI (14D)
38.5
Price vs SMA 50
-12.4%
Price vs SMA 200
+1.9%
Avg volume (3M)
291,284
Relative volume
3.0
Average dollar volume
$3.32M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
338.78M

Valuation

12 metrics
P / E (TTM)
101.9
Trailing earnings · reciprocal yield 1.0%
PEG ratio
—
EV / revenue
4.1×
reciprocal yield 24.2%
EV / EBITDA
41.4×
reciprocal yield 2.4%
EV / EBIT
55.9×
reciprocal yield 1.8%
P / sales
3.8×
reciprocal yield 26.1%
P / book
7.0
reciprocal yield 14.3%
FCF yield
-1.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
1.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-19

Profitability

9 metrics
Gross margin
53.7%
Operating margin
7.4%
Trailing 12 months
Net margin
3.8%
Gross profit (TTM)
$478.16M
Operating profit (TTM)
$65.75M
Net income (TTM)
$33.50M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-5.1%
Effective tax rate
-16.2%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.23

Growth

11 metrics
Revenue growth YoY
+55.6%
Year over year
Net income growth YoY
-121.2%
Revenue (TTM)
$890.78M
Trailing 12 months
EPS growth YoY
-121.6%
Shares change YoY
+1.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
6.9%
Return on assets
2.5%
Debt / equity
1.0
Current ratio
2.0
EBITDA (TTM)
$88.82M
Free cash flow (TTM)
−$45.49M
Quick ratio
1.9
Interest coverage
1.6
Net debt / EBITDA
3.0
Return on invested capital
—
Trailing 12 months
Net cash
−$263.16M
Latest balance sheet
Cash & equivalents
$251.91M
Total assets
$1.36B
Total debt
$405.02M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.01M
Capital expenditures (TTM)
$33.48M
R&D (TTM)
$213.49M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
24.0%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
62
13F filer change QoQ
+22
Institutional ownership
0.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+21.6%
Holder tenure
3.5
Price vs estimated holder cost
+19.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
38 / 100

Insider activity

2 metrics
Net insider buying (90D)
$19,998
Insider-sentiment score
73 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2007191 CUSIP 87961M105 13F (30d) 10 filings 10 filers Visit website Investor relations